Filing Flows › Intellia Therapeutics (NTLA) › Q2 2026 › vs Q2 2025
Intellia Therapeutics (NTLA) Q2 2026 vs Q2 2025 (year over year)
Intellia Therapeutics's revenue fell $6.6M (-46%) from $14.2M in Q2 2025 to $7.7M in Q2 2026.
Intellia Therapeutics, Q2 2026: revenue $7.7M (-46% year over year), net loss $107M, operating cash flow −$83.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $7.7M | $14.2M | −$6.6M | -46% |
| Other income, net | $6.1M | $8.7M | −$2.6M | -30% |
| Net loss | $107M | $101M | $5.4M | +5% |
| Costs & expenses | $120M | $124M | −$3.8M | -3% |
| Operating costs | $120M | $124M | −$3.8M | -3% |
| Research & development | $82.6M | $97.0M | −$14.4M | -15% |
| General & admin | $37.8M | $27.2M | $10.6M | +39% |
| Operating cash sources | $107M | $101M | $5.4M | +5% |
| Depreciation & amortization | $2.1M | $2.5M | −$400K | -16% |
| Share-based compensation | $18.1M | $22.0M | −$4.0M | -18% |
| Working capital & other | $3.3M | −$22.9M | $26.2M | — |
| Cash used in operations | $83.1M | $99.6M | −$16.5M | -17% |
| Net loss absorbed | $107M | $101M | $5.4M | +5% |
Questions
How much did Intellia Therapeutics's revenue grow year over year in Q2 2026?
Intellia Therapeutics's revenue fell $6.6M (-46%) from $14.2M in Q2 2025 to $7.7M in Q2 2026.